About the Company
pliant therapeutics is focused on discovering, developing and commercializing breakthrough treatments for fibrotic diseases. by harnessing the therapeutic potential of integrin biology and tgf-β modulation, pliant aims to prevent or even reverse fibrosis to address the needs of many patients. the company also aims to build a patient registry for certain areas of fibrotic disease to both increase understanding of natural disease progression, and fuel biomarker discovery. pliant’s co-founders include world-renowned researchers from university of california, san francisco (ucsf), who bring broad experience in fibrosis biology and small molecule chemistry. together, the pliant team is dedicated to translating scientific advances in fibrosis biology into novel therapies for patients in need.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $PLRX News
Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis
Acceptance by European Union and other global health authorities of the pivotal, adaptivePhase 2b/3 trial will significantly ...
Earnings Preview: Pliant Therapeutics, Inc. (PLRX) Q4 Earnings Expected to Decline
The market expects Pliant Therapeutics, Inc. (PLRX) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2023. This widely-known ...
Pliant Therapeutics: Strong Buy Rating on Promising Pipeline and Solid Financials
Begin your TipRanks Premium journey today. Pliant Therapeutics (PLRX) Company Description: Pliant Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing ...
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results
Feb. 27, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment ...
Pliant Therapeutics Inc Ordinary Shares
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Pliant Therapeutics to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel ...
Earnings Preview: Pliant Therapeutics, Inc. (PLRX) Q4 Earnings Expected to Decline
The market expects Pliant Therapeutics, Inc. (PLRX) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2023. This widely-known ...
Pliant Therapeutics, Inc.: Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis
Acceptance by European Union and other global health authorities of the pivotal, adaptivePhase 2b/3 trial will significantly shorten bexotegrast's time to Phase 3 data Upsized Oxford Finance debt faci ...
Loading the latest forecasts...